TAK - Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial | Benzinga
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib) in the U.S.
Exkivity is indicated for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-based chemotherapy.
Takeda intends to similarly initiate voluntary withdrawal globally where Exkivity is approved and is working with regulators in other countries ...